NCT00437619View on ClinicalTrials.gov

A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Psoriasis
Interventions
DRUG

calcipotriol hydrate [Daivonex]

50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a \>50% response to Daivobet from weeks 0-4.

Trial Locations (10)

66087-670

Belém

30150-221

Belo Horizonte

18618-000

Botucatu

70840-901

Brasília

13060-803

Campinas

8000001003

Curitiba

20020-020

Rio de Janeiro

22470-220

Rio de Janeiro

41110-170

Salvador

05403-900

São Paulo

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00437619 - A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis. | Biotech Hunter | Biotech Hunter